Patents by Inventor Frank Traganos

Frank Traganos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110214680
    Abstract: Aspects of the invention concern methods for detecting, identifying and evaluating tobacco and tobacco products to determine the potential that these compositions have to contribute to a tobacco-related disease. It is based, at least in part; on the discovery that exposure of pulmonary cells to smoke or smoke condensate obtained from tobacco or tobacco products induces double stranded breaks in cellular DNA, which were efficiently detected using assays that measure the presence, absence, or amount of phosphorylation of the histone, H2AX.
    Type: Application
    Filed: March 28, 2011
    Publication date: September 8, 2011
    Applicants: VECTOR TOBACCO, INC., New York Medical College
    Inventors: Anthony P. Albino, Ellen D. Jorgensen, Frank Traganos, Zbigniew Darzynkiewicz, Wendy Jin
  • Publication number: 20100132726
    Abstract: Aspects of the invention concern methods for detecting, identifying and evaluating tobacco and tobacco products to determine the potential that these compositions have to contribute to a tobacco-related disease. It is based, at least in part; on the discovery that exposure of pulmonary cells to smoke or smoke condensate obtained from tobacco or tobacco products induces double stranded breaks in cellular DNA, which were efficiently detected using assays that measure the presence, absence, or amount of phosphorylation of the histone, H2AX.
    Type: Application
    Filed: February 5, 2010
    Publication date: June 3, 2010
    Applicant: VECTOR TOBACCO, INC.
    Inventors: Anthony P. Albino, Ellen D. Jorgensen, Frank Traganos, Zbigniew Darzynkiewicz, Wendy Jin
  • Patent number: 7662565
    Abstract: Aspects of the invention concern methods for detecting, identifying and evaluating tobacco and tobacco products to determine the potential that these compositions have to contribute to a tobacco-related disease. It is based, at least in part; on the discovery that exposure of pulmonary cells to smoke or smoke condensate obtained from tobacco or tobacco products induces double stranded breaks in cellular DNA, which were efficiently detected using assays that measure the presence, absence, or amount of phosphorylation of the histone, H2AX.
    Type: Grant
    Filed: May 11, 2005
    Date of Patent: February 16, 2010
    Assignee: Vector Tobacco, Inc.
    Inventors: Anthony P. Albino, Ellen D. Jorgensen, Frank Traganos, Zbigniew Darzynkiewicz, Wendy Jin
  • Publication number: 20080227088
    Abstract: Aspects of the invention concern methods for detecting, identifying and evaluating tobacco and tobacco products to determine the potential that these compositions have to contribute to a tobacco-related disease. It is based, at least in part; on the discovery that exposure of pulmonary cells to smoke or smoke condensate obtained from tobacco or tobacco products induces double stranded breaks in cellular DNA, which were efficiently detected using assays that measure the presence, absence, or amount of phosphorylation of the histone, H2AX.
    Type: Application
    Filed: May 11, 2005
    Publication date: September 18, 2008
    Inventors: Anthony P. Albino, Ellen D. Jorgensen, Frank Traganos, Zbigniew Darzynkiewicz, Wendy Jin
  • Patent number: 7070943
    Abstract: Methods, reagents, and kits are provided that permit flow cytometric determination of the phosphorylation status of retinoblastoma susceptibility gene protein (pRB) in individual cells. Methods are described that permit the hypophosphorylated, active, form of pRB to be measured either as an absolute quantity or as a proportion of total cellular pRB. Further described are methods that permit pRB phosphorylation status to be correlated with cell cycle phase and with protein components of the cell cycle. Screening of chemical compounds for antiproliferative and antineoplastic activity using the flow cytometric assays is demonstrated. Reagent kits that facilitate the subject methods are also provided.
    Type: Grant
    Filed: September 29, 2004
    Date of Patent: July 4, 2006
    Assignee: Becton Dickinson and Company
    Inventors: Zbigniew Darzynkiewicz, Frank Traganos, Gloria Juan, Stefan Gruenwald
  • Publication number: 20050042694
    Abstract: Methods, reagents, and kits are provided that permit flow cytometric determination of the phosphorylation status of retinoblastoma susceptibility gene protein (pRB) in individual cells. Methods are described that permit the hypophosphorylated, active, form of pRB to be measured either as an absolute quantity or as a proportion of total cellular pRB. Further described are methods that permit pRB phosphorylation status to be correlated with cell cycle phase and with protein components of the cell cycle. Screening of chemical compounds for antiproliferative and antineoplastic activity using the flow cytometric assays is demonstrated. Reagent kits that facilitate the subject methods are also provided.
    Type: Application
    Filed: September 29, 2004
    Publication date: February 24, 2005
    Inventors: Zbigniew Darzynkiewicz, Frank Traganos, Gloria Juan, Stefan Gruenwald
  • Patent number: 6821740
    Abstract: Methods, reagents, and kits are provided that permit flow cytometric determination of the phosphorylation status of retinoblastoma susceptibility gene protein (pRB) in individual cells. Methods are described that permit the hypophosphorylated, active, form of pRB to be measured either as an absolute quantity or as a proportion of total cellular pRB. Further described are methods that permit pRB phosphorylation status to be correlated with cell cycle phase and with protein components of the cell cycle. Screening of chemical compounds for antiproliferative and antineoplastic activity using the flow cytometric assays is demonstrated. Reagent kits that facilitate the subject methods are also provided.
    Type: Grant
    Filed: February 24, 1999
    Date of Patent: November 23, 2004
    Assignee: Becton, Dickinson and Company
    Inventors: Zbigniew Darzynkiewicz, Frank Traganos, Gloria Juan, Stefan Gruenwald
  • Publication number: 20030108952
    Abstract: Methods, reagents, and kits are provided that permit flow cytometric determination of the phosphorylation status of retinoblastoma susceptibility gene protein (pRB) in individual cells. Methods are described that permit the hypophosphorylated, active, form of pRB to be measured either as an absolute quantity or as a proportion of total cellular pRB. Further described are methods that permit pRB phosphorylation status to be correlated with cell cycle phase and with protein components of the cell cycle. Screening of chemical compounds for antiproliferative and antineoplastic activity using the flow cytometric assays is demonstrated. Reagent kits that facilitate the subject methods are also provided.
    Type: Application
    Filed: February 24, 1999
    Publication date: June 12, 2003
    Inventors: ZBIGNIEW DARZYNKIEWICZ, FRANK TRAGANOS, GLORIA JUAN, STEFAN GRUENWALD
  • Patent number: 6417343
    Abstract: Methods for immunocytochemical detection and isolation of RNA.
    Type: Grant
    Filed: October 16, 1997
    Date of Patent: July 9, 2002
    Assignee: New York Medical College
    Inventors: Zbigniew Darzynkiewicz, Frank Traganos, Gloria Juan
  • Patent number: 5912126
    Abstract: The invention pertains to the field of DNA detection for basic research, medical diagnostic testing, and forensic testing. Methods are provided for end labeling of DNA strands without a denaturation step so that cellular morphology can be better preserved. The DNA strands are first incubated with a halogenated deoxynucleotide triphosphate, such as brominated deoxyuridine triphosphate (BrdUTP), and an enzyme which can catalyze the addition of the halogenated deoxynucleotide to the 3' OH ends of the DNA strand, such as terminal deoxynucleotidyl transferase (TdT). The resulting modified DNA strands are then incubated with a labeled antibody, such as a fluoresceinated monoclonal antibody, that binds specifically to the halogenated deoxynucleotide. The label is then detected, e.g., by flow cytometry. The methods have utility in detecting apotosis, DNA synthesis and/or repair, and as general methods for end labeling DNA.
    Type: Grant
    Filed: October 22, 1996
    Date of Patent: June 15, 1999
    Inventors: Zbigniew Darzynkiewicz, Xun Li, Frank Traganos